https://www.selleckchem.com/pr....oducts/pmsf-phenylme
esponder versus progressor. Our study provides a deep cellular analysis of on-treatment changes during chemo-immunotherapy for advanced TNBC, demonstrating not only feasibility of single-cell analyses on serial tumor biopsies but also the heterogeneity of TNBC and differences in on-treatment changes in responder versus progressor.Hyperprolactinemia can have different causes physiological, pharmacological, and pathological. When investigating the etiology of hyperprolactinemia, clinicians need to be aware of se
Mi piace
Commento
Condividi
